A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, according to its chief corporate brand officer Lina Polimeni.

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. | Eli Lilly has spent the last several years reintroducing itself to the public via a ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...